Potential Non Small Cell Lung Cancer Combo Therapy Tops AJPB Week in Review

Top news of the week from The American Journal of Pharmacy Benefits.

5. Benefits of Medicaid Expansion Found to Outweigh Negatives

Study finds Medicaid expansion associated with increases in coverage, service use, quality of care, and spending. Read more.

4. Esketamine Nasal Spray Shows Promise Depression Relapse

Esketamine is a glutamate receptor modulator capable of restoring synaptic connections in the brains of patients with depression. Read more.

3. Lenalidomide Combo Shows Promise as Frontline Therapy for Follicular Lymphoma

Rituximab (Rituxan) and lenalidomide (Revlimid) showed similar efficacy to rituximab plus chemotherapy, according to findings presented at the 2018 ASCO Annual Meeting. Read more.

2. Medicare Part A Will Become Insolvent in 2026

Trustees for Medicare said that Medicare Part A, which covers hospital bills, will become insolvent in 2026, 3 years earlier than the projection last year in its annual report. Read more.

1. Combination Effective Treating Non Small Cell Lung Cancer

Pegilodecakin (AM0010) with nivolumab (Opdivo) or pembrolizumab (Keytruda) induced an overall response rate in 41% in patients with advanced non—small cell lung cancer, according to findings presented at the 2018 ASCO Annual meeting. Read more.